medicine

Auto Added by WPeMatico

Better Health raises $3.5M seed round to reinvent medical supply shopping through e-commerce

The home medical supply market in the U.S. is significant and growing, but the way that Americans go about getting much-needed medical supplies, particularly for those with chronic conditions, relies on outdated and clumsy sales mechanisms that often have very poor customer experiences. New startup Better Health aims to change that, with an e-commerce approach to serving customers in need of medical supplies for chronic conditions, and it has raised $3.5 million in a new seed round to pursue its goals.

Better Health estimates the total value of the home medical supplies market in the U.S., which covers all reimbursable devices and supplies needed for chronic conditions, including things like colostomy bags, catheters, mobility aids, insulin pumps and more, is around $60 billion annually. But the market is obviously a specialized one relative to other specialized goods businesses, in part because it requires working not only with customers who make the final decisions about what supplies to use, but also payers, who typically foot the bill through insurance reimbursements.

The other challenge is that individuals with chronic care needs often require a lot of guidance and support when making the decision about what equipment and supplies to select — and the choices they make can have a significant impact on quality of life. Better Health co-founder and CEO Naama Stauber Breckler explained how she came to identify the problems in the industry, and why she set out to address them.

“The first company I started was right out of school, it’s called CompactCath,” she explained in an interview. “We created a novel intermittent catheter, because we identified that there’s a gap in the existing options for people with chronic bladder issues that need to use a catheter on a day-to-day basis […] In the process of bringing it to market, I was exposed to the medical devices and supplies industry. I was just shocked when I realized how hard it is for people today to get life-saving medical supplies, and basically realized that it’s not just about inventing a better product, there’s kind of a bigger systematic problem that locks consumer choice, and also prevents innovation in the space.”

Stauber Breckler’s founding story isn’t too dissimilar from the founding story of another e-commerce pioneer: Shopify. The now-public heavyweight originally got started when founder Tobi Lütke, himself a software engineer like Stauber Breckler, found that the available options for running his online snowboard store were poorly designed and built. With Better Health, she’s created a marketplace, rather than a platform like Shopify, but the pain points and desire to address the problem at a more fundamental level are the same.

Better Health head of Product Adam Breckler, left, and CEO Naama Stauber Breckler, right. Image Credits: Better Health

With CompactCath, she said they ended up having to build their own direct-to-consumer marketing and sales product, and through that process, they ended up talking to thousands of customers with chronic conditions about their experiences, and what they found exposed the extent of the problems in the existing market.

“We kept hearing the same stories again, and again — it’s hard to find the right supplier, often it’s a local store, the process is extremely manual and lengthy and prone to errors, they get the surprise bills they weren’t expecting,” Stauber Breckler said. “But mostly, it’s just that there is this really sharp drop in care, from the time that you have a surgery or you were diagnosed, to when you need to now start using this device, when you’re essentially left at home and are given a general prescription.”

Unlike in the prescription drug market, where your choices essentially amount to whether you pick the brand name or the generic, and the outcome is pretty much the same regardless, in medical supplies which solution you choose can have a dramatically different effect on your experience. Customers might not be aware, for example, that something like CompactCath exists, and would instead choose a different catheter option that limits their mobility because of how frequently it needs changing and how intensive the process is. Physicians and medical professionals also might not be the best to advise them on their choice, because while they’ve obviously seen patients with these conditions, they generally haven’t lived with them themselves.

“We have talked to people who tell us, ‘I’ve had an ostomy for 19 years, and this is the first time I don’t have constant leakages’ or someone who had been using a catheter for three years and hasn’t left her house for more than two hours, because they didn’t feel comfortable with the product that they had to use it in a public restroom,” Stauber Breckler said. “So they told us things like ‘I finally went to visit my parents, they live in a town three hours away.’ ”

Better Health can provide this kind of clarity to customers because it employs advisors who can talk patients through the equipment selection process with one-to-one coaching and product use education. The startup also helps with navigating the insurance side, managing paperwork, estimating costs and even arguing the case for a specific piece of equipment in case of difficulty getting the claim approved. The company leverages peers who have firsthand experience with the chronic conditions it serves to help better serve its customers.

Already, Better Health is a Medicare-licensed provider in 48 states, and it has partnerships in place with commercial providers like Humana and Oscar Health. This funding round was led by 8VC, a firm with plenty of expertise in the healthcare industry and an investor in Stauber Breckler’s prior ventures, and includes participation from Caffeinated Capital, Anorak Ventures and angels Robert Hurley and Scott Flanders of remote health pioneer eHealth.

Powered by WPeMatico

Serimmune launches new immune response mapping service for COVID-19

Immune intelligence startup Serimmune hopes to better understand the relationship between antibody epitopes (the parts of antigen molecules that bind to antibodies) and the SARS-CoV-2 virus.

The company’s proprietary technology, originally developed at UC Santa Barbara, provides a new and specific way of mapping the entire array of an individual’s antibodies through a small blood sample. They do this through the use of a bacterial peptide display — a sort of screening mechanism that can isolate plasmid DNA from antibody-bound bacteria in the sample. This DNA can then be sequenced to identify epitopes, which provide information about which antigens someone may have been exposed to, as well as how their immune system responded to them.

“It’s a very highly multiplexed and exquisitely specific way of looking at the epitopes found by antibodies in a specimen,” said Serimmune CEO Noah Nasser, who has a degree in molecular biology from UC San Diego and has previously worked for several diagnostics companies.

This week, Serimmune announced the launch of a new application of their core technology to help understand the disease states of and immune responses to SARS-CoV-2, the virus that causes COVID-19.

“So what we do is we take these antibody profiles we build, and we’re able to then map those back with about a 12 amino acid specificity to the SARS-CoV-2 proteome,” said Nasser. “And what we find is that antibody expression is highly correlated to disease state, so we can distinguish mild, moderate, severe and asymptomatic disease on the basis of antibodies that are present in the specimen.”

The more patient data Serimmune can collect, the better its core technology becomes at finding patterns across different antigen exposure and disease severity. Noticing those patterns sooner won’t only help physicians and researchers to better understand how the SARS-CoV-2 virus operates, but can also inform new approaches to diagnostics, treatments and vaccines for any antigen.

Serimmune’s launch of its new COVID antibody epitope mapping service is a way of making this data more accessible to customers like vaccine companies, government agencies and academic labs that have shown interest in better understanding the immune response to SARS-CoV-2.

“The key was to zero in on the information that researchers wanted to know and standardize that,” said Nasser. “We can actually now provide these results back in as few as two days from sample receipt.”

Beyond this new service, Serimmune also has plans to launch a longitudinal clinical study on immunity to SARS-CoV-2. Using a painless at-home collection kit, study participants send in small blood samples to Serimmune, which then uses its core technology to outline an individual immunity map.

“We provide their results back to them in the form of a personal immune landscape to COVID,” said Nasser. “And what we’re trying to do is to understand over time how that immune response changes, and what happens to that immune response on repeated exposure to COVID.”

The mapping technology is now so specific that it can tell whether a patient has antibodies from natural exposure to the SARS-CoV-2 virus or from a vaccine, he added.

While the primary focus for Serimmune remains these applications to the COVID-19 pandemic for now, Nasser also mentioned that the company has plans to move into personalized medicine, potentially offering their mapping service directly to interested patients.

“We believe that this has value to individual patients in understanding their immune status and what antigens they’ve been exposed to,” he said. Until then, Serimmune plans to continue growing its database with more patient samples.

Powered by WPeMatico

Sano Genetics, a startup helping with Long COVID research, raises £2.5M in seed funding

Sano Genetics, a startup with a broad mission to support personalised medicine research by increasing participation in clinical trials, has raised £2.5 million in seed funding.

The round is led by Episode1 Ventures, alongside Seedcamp, Cambridge Enterprise, January Ventures and several Europe and U.S.-based angel investors. It adds to £500,000 in pre-seed funding from 2018.

Sano Genetics says part of the new capital will be to fund free at-home DNA testing kits for 3,000 people affected by Long COVID. It will also further invest in the development of its tech platform and grow the team.

Founded in 2017 by Charlotte Guzzo, Patrick Short and William Jones after they met at Cambridge University while studying genomics as postgrads, Sano Genetics has built what it describes as a “private-by-design” tech platform to help patients take part in medical research and clinical trials. This includes at-home genetic testing capabilities, and is seeing the company support research into multiple sclerosis, ankylosing spondylitis, NAFLD and ulcerative colitis2, with a research programme for Parkinson’s disease on the agenda for later in 2021.

“For participants in medical research, the process is not user friendly,” says Sano Genetics CEO Patrick Short. “There is usually little to no benefit for participants beyond altruism, taking part is difficult and time-consuming and people are also concerned about the privacy of their sensitive genetic and medical information.

“[Therefore], for researchers in biotech, pharma and academia, it is very difficult to attract and retain research participants, which adds substantial costs and time to their research. In particular for research involving genetics and precision therapies, it is doubly challenging to find the ‘right’ patients because genetic testing is not routine in the healthcare system”.

To help solve this, Sano Genetics matches relevant participants to research via its platform. It then makes participation easier by enabling at-home genetic testing and by guiding participants through the process.

“The system is designed so users know exactly what will happen with their data, and we give them straightforward ways to control their data,” explains Short. “We keep our users engaged and involved in the research process by giving them updates on the research they have been a part of, and with free personalised content including genetic reports, and stories from other people like them on our blog”.

A typical end user is someone who has a chronic or rare disease and is using the platform to take part in research that helps them personally (e.g. access to a new therapy via a clinical trial) or to help others like them.

Meanwhile, Sano Genetics generates revenue by charging biotech and pharma companies fees to find the right patients for their studies. “The typical study for us consists of a set-up fee, a per-test fee for our at-home genetic testing and analysis, and a fee for each referral we make of an interested and eligible participant to their research study,” adds the Sano Genetics CEO.

Powered by WPeMatico

Buildots raises $16M to bring computer vision to construction management

Buildots, a Tel Aviv and London-based startup that is using computer vision to modernize the construction management industry, today announced that it has raised $16 million in total funding. This includes a $3 million seed round that was previously unreported and a $13 million Series A round, both led by TLV Partners. Other investors include Innogy Ventures, Tidhar Construction Group, Ziv Aviram (co-founder of Mobileye & OrCam), Magma Ventures head Zvika Limon, serial entrepreneurs Benny Schnaider and  Avigdor Willenz, as well as Tidhar chairman Gil Geva.

The idea behind Buildots is pretty straightforward. The team is using hardhat-mounted 360-degree cameras to allow project managers at construction sites to get an overview of the state of a project and whether it remains on schedule. The company’s software creates a digital twin of the construction site, using the architectural plans and schedule as its basis, and then uses computer vision to compare what the plans say to the reality that its tools are seeing. With this, Buildots can immediately detect when there’s a power outlet missing in a room or whether there’s a sink that still needs to be installed in a kitchen, for example.

“Buildots have been able to solve a challenge that for many seemed unconquerable, delivering huge potential for changing the way we complete our projects,” said Tidhar’s Geva in a statement. “The combination of an ambitious vision, great team and strong execution abilities quickly led us from being a customer to joining as an investor to take part in their journey.”

The company was co-founded in 2018 by Roy Danon, Aviv Leibovici and Yakir Sundry. Like so many Israeli startups, the founders met during their time in the Israeli Defense Forces, where they graduated from the Talpiot unit.

“At some point, like many of our friends, we had the urge to do something together — to build a company, to start something from scratch,” said Danon, the company’s CEO. “For us, we like getting our hands dirty. We saw most of our friends going into the most standard industries like cloud and cyber and storage and things that obviously people like us feel more comfortable in, but for some reason we had like a bug that said, ‘we want to do something that is a bit harder, that has a bigger impact on the world.’ ”

So the team started looking into how it could bring technology to traditional industries like agriculture, finance and medicine, but then settled upon construction thanks to a chance meeting with a construction company. For the first six months, the team mostly did research in both Israel and London to understand where it could provide value.

Danon argues that the construction industry is essentially a manufacturing industry, but with very outdated control and process management systems that still often relies on Excel to track progress.

Image Credits: Buildots

Construction sites obviously pose their own problems. There’s often no Wi-Fi, for example, so contractors generally still have to upload their videos manually to Buildots’ servers. They are also three dimensional, so the team had to develop systems to understand on what floor a video was taken, for example, and for large indoor spaces, GPS won’t work either.

The teams tells me that before the COVID-19 lockdowns, it was mostly focused on Israel and the U.K., but the pandemic actually accelerated its push into other geographies. It just started work on a large project in Poland and is scheduled to work on another one in Japan next month.

Because the construction industry is very project-driven, sales often start with getting one project manager on board. That project manager also usually owns the budget for the project, so they can often also sign the check, Danon noted. And once that works out, then the general contractor often wants to talk to the company about a larger enterprise deal.

As for the funding, the company’s Series A round came together just before the lockdowns started. The company managed to bring together an interesting mix of investors from both the construction and technology industries.

Now, the plan is to scale the company, which currently has 35 employees, and figure out even more ways to use the data the service collects and make it useful for its users. “We have a long journey to turn all the data we have into supporting all the workflows on a construction site,” said Danon. “There are so many more things to do and so many more roles to support.”

Image Credits: Buildots

Powered by WPeMatico

Activ Surgical raises $15 million to advance autonomous and collaborative robotic surgery

Boston-based startup Activ Surgical has raised a $15 million round of venture funding led by ARTIS Ventures, and including participation from LRVHealth, DNS Capital, GreatPoint Ventures, Tao Capital Partners and Rising Tide VC. The round will help Activ continue to develop and expand availability of its software platform, which it launched to market in May.

Activ Surgical’s ActivEdge platform uses data collected from surgical implements outfitted with sensors created by the company to collect real-time data during the actual surgical process. That data is then used to inform the development of machine learning and AI-based visualizations that can provide guidance to surgeons and surgical systems to help them reduce the occurrence of potential errors, and ultimately improve outcomes for patients.

The company’s primary aim is to bring technological innovation to the sphere of surgical vision, which still relies primarily on methods like using fluorescent dyes that date back more than 70 years. Activ wants to use computer vision to provide real-time visual insight into things that surgeons wouldn’t be able to see on their own — and ultimately to use those insights to power the next generation of both collaborative surgical robots and eventually even fully autonomous robotic surgical procedures.

ActivSight is the company’s first product in its ActivEdge platform offering, and is a small, connected imaging coddle that can be attached to existing laparoscopic and arthroscopic surgical instruments. The company is currently tracking toward getting their hardware cleared by the FDA for use by Q4 this year, and are working with eight hospital partners for pilot projects in the U.S.

The company has raised a total of $32 million in funding to date.

Powered by WPeMatico

YC startup Felix wants to replace antibiotics with programmable viruses

Right now the world is at war. But this is no ordinary war. It’s a fight with an organism so small we can only detect it through use of a microscope — and if we don’t stop it, it could kill millions of us in the next several decades. No, I’m not talking about COVID-19, though that organism is the one on everyone’s mind right now. I’m talking about antibiotic-resistant bacteria.

You see, more than 700,000 people died globally from bacterial infections last year — 35,000 of them in the U.S. If we do nothing, that number could grow to 10 million annually by 2050, according to a United Nations report.

The problem? Antibiotic overuse at the doctor’s office or in livestock and farming practices. We used a lot of drugs over time to kill off all the bad bacteria — but it only killed off most, not all, of the bad bacteria. And, as the famous line from Jeff Goldblum in Jurassic Park goes, “life finds a way.”

Enter Felix, a biotech startup in the latest Y Combinator batch that thinks it has a novel approach to keeping bacterial infections at bay – viruses.

Phage killing bacteria in a petri dish

It seems weird in a time of widespread concern over the corona virus to be looking at any virus in a good light but as co-founder Robert McBride explains it, Felix’s key technology allows him to target his virus to specific sites on bacteria. This not only kills off the bad bacteria but can also halt its ability to evolve and once more become resistant.

But the idea to use a virus to kill off bacteria is not necessarily new. Bacteriophages, or viruses that can “infect” bacteria, were first discovered by an English researcher in 1915 and commercialized phage therapy began in the U.S. in the 1940’s through Eli Lilly and Company. Right about then antibiotics came along and Western scientists just never seemed to explore the therapy further.

However, with too few new solutions being offered and the standard drug model not working effectively to combat the situation, McBride believes his company can put phage therapy back at the forefront.

Already Felix has tested its solution on an initial group of 10 people to demonstrate its approach.

Felix researcher helping cystic fibrosis patient Ella Balasa through phage therapy

“We can develop therapies in less time and for less money than traditional antibiotics because we are targeting orphan indications and we already know our therapy can work in humans,” McBride told TechCrunch . “We argue that our approach, which re-sensitizes bacteria to traditional antibiotics could be a first line therapy.”

Felix plans to deploy its treatment in those suffering from cystic fibrosis first as there is no cure for this disease, which tends to require a near constant stream of antibiotics to combat lung infections.

The next step will be to conduct a small clinical trial involving 30 people, then, as the scientific research and development model tends to go, a larger human trial before seeking FDA approval. But McBride hopes his viral solution will prove itself out in time to help the coming onslaught of antibiotic resistance.

“We know the antibiotic resistant challenge is large now and is only going to get worse,” McBride said. “We have an elegant technological solution to this challenge and we know our treatment can work. We want to contribute to a future in which these infections do not kill more than 10 million people a year, a future we can get excited about.”

Powered by WPeMatico

Healthcare startups Nurx and Carbon Health ship at-home COVID-19 test sample kits

Efforts to get at-home test kits for the COVID-19 coronavirus are ramping up quickly, and two more health industry startups are bringing their own products to market, with both Carbon Health and Nurx starting to ship their own in-home sample collection kits.

Both of these new offerings are the same in terms of approach to testing: They deliver swab-based sample collection hardware that people can use at home to collect a mucus sample, which they then ship back using included, safety approved, projective packaging to be tested by one of the existing FDA-approved commercial labs across the country.

These tests follow the PCR-based method, which tests for the genetic presence of the COVID-19 virus in a patient. These have a high degree of accuracy, at least when performed in a controlled setting and administered by a medical professional, and are the same tests that are available via drive-through testing stations being set up by state agencies.

At-home use is relatively new to market, and could introduce some potential for error in the collection part of the process, but both Carbon Health and Nurx are offering consultation with medical professionals to help ensure that samples are collected properly, and that results, when available, are correctly interpreted and provided with guidance on next steps for those taking the tests.

None of these tests are free — the Carbon Health test costs $167.50, and the Nurx test costs $181, including shipping and assessment. These are in line with other offerings, including the one from Everlywell we covered earlier this week, which retails for $135. These are described as essentially at-cost prices, and all parties say they are subject to coverage by FSA or HSA money, or potentially by insurers depending on a person’s plan.

One big question around these types of tests is how much supply will be available. Nasopharyngeal swabs used for the in-person type of testing are already reportedly in short supply in some regions, and testing needs are only growing. Carbon is using different swabs to collect a simple saliva sample, which it notes are not in as short supply as the nasopharyngeal version. Other types of tests, including a “serological” one being developed by startup Scanwell, instead work by analyzing a patient’s blood, and could provide some relief for the swab-based tests, especially now that the FDA has expanded its emergency guidance to include their use.

Nurx, which also offers at-home HPV screening, says that it will have 10,000 kits available to patients “over the coming weeks,” and hopes to expand to cover “over 100,000 patients” in the “near future.” Carbon Health CEO and co-founder Eren Bali tells me that it should ramp to around “10,000 per day capacity in about two weeks,” through its medical device partner Curative Inc., and that it can do 50 per day today, with an estimated increase to 150 per day by Monday and 1,000 per day by end of week.

All of these tests are gated by a screening and assessment questionnaire, and the round-trip time is likely to take a few days even with round-trip shipping due to testing times. It may seem like a lot of these are popping up, but these startups at least have proven track records in healthcare services, and there will be a need for very widespread testing in order for any broad attempt to flatten the curve of the virus to prove successful, so expect more of these providers to come on line.

Powered by WPeMatico

WW launches Kurbo, a hotly debated ‘healthy eating’ app aimed at kids

Kurbo Health, a mobile weight loss solution designed to tackle childhood obesity which was acquired for $3 million by WW (the rebranded Weight Watchers), has now relaunched as Kurbo by WW — and not without some controversy. Pre-acquisition, the startup was focused on democratizing access to research, behavior modification techniques and other tools that were previously only available through expensive programs run by hospitals or other centers.

As a WW product, however, there are concerns that parents putting kids on “diets” will lead to increased anxiety, stress and disordered eating — in other words, Kurbo will make the problem worse, rather than solving it.

*If* you are worried about your child’s health/lifestyle, give them plenty of nutritious food and make sure they get plenty of fun exercise that helps their mental health. And don’t weigh them. Don’t burden them with numbers, charts or “success/failure.” It’s a slippery slope.

— Jameela Jamil 🌈 (@jameelajamil) August 14, 2019

The Kurbo app first launched at TechCrunch Disrupt NY 2014. Founder Joanna Strober, a venture investor and board member at BlueNile and eToys, explained she was driven to develop Kurbo after struggling to help her own child. Mainly, she came across programs that cost money, were held at inconvenient times for working parents or were dubbed “obesity centers” — with which no child wanted to be associated.

Her child found eventual success with the Stanford Pediatric Weight Loss Program, but this involved in-person visits and pen-and-paper documentation.

Together with Kurbo Health’s co-founder Thea Runyan, who has a Master’s in Public Health and had worked at the Stanford center for 12 years, the team realized the opportunity to bring the research to more people by creating a mobile, data-driven program for kids and families.

They licensed Stanford’s program, which then became Kurbo Health.

FoodSystem Phone

The company raised funds from investors, including Signia Ventures, Data Collective, Bessemer Venture Partners and Promus Ventures, as well as angels like Susan Wojcicki, CEO of YouTube; Greg Badros, former VP Engineering and Product at Facebook; and Esther Dyson (EdVenture), among others.

At launch, the app was designed to encourage healthier eating patterns without parents actually being able to see the child’s food diary. Instead, parents set a reward that was doled out simply for the child’s participation. That is, the parents couldn’t see what the child ate, specifically, which allowed them to stop playing “food police.”

ProfileStreak Phone

Unlike adult-oriented apps like MyFitnessPal or Noom, kids wouldn’t see metrics like calories, sugars, carbs and fat, but instead had their food choices categorized as “red,” “yellow” and “green.” However, no foods were designated as “off limits,” as it instead encouraged fewer reds and more greens.

The program also included an option for virtual coaching.

As a WW product, the program has remained somewhat the same. There are still the color-coded food categorizations and optional live coaching, via a subscription. Parents are still involved, now with updates after coaching calls or the option to join coaching sessions. The app also now includes tools that teach meditation, recipe videos and games that focus on healthy lifestyles. Subscribers gain access to one-on-one 15-minute virtual sessions with coaches whose professional backgrounds include counseling, fitness and other nutrition-related fields.

However, there are also things like a place to track measurements, goals like “lose weight” and Snapchat-style “tracking streaks.”

Home Tracked Phone

While the original program was designed to be a solution for parents with children who would have otherwise had to seek expensive medical help for obesity issues, the association with parent company and acquirer WW has led to some backlash.

CoachingChat Phone

Today, body positivity and fat acceptance movements have gone mainstream, encouraging people to be confident in their own bodies and not hate themselves for being overweight. The general thinking is that when people respect themselves, they become more likely to care for themselves — and this will extend to making healthier food and lifestyle choices.

Meanwhile, food tracking and dieting programs often lead to failure and shame — especially when people start to think of some food as “bad” or a “cheat,” instead of just something to be eaten in moderation. And excessive tracking can even lead to disordered eating patterns for some people, studies have found.

In addition, WW has already been under fire for extending its weight loss program to teens 13-17 for free, and the launch of what’s seen as a “dieting app for kids” as part of WW’s broader family-focused agenda certainly isn’t helping the backlash.

That said, when positive reinforcement is used correctly, it can work for weight loss. As TIME reported, the red-yellow-green traffic light approach was effective in adults in one independent study by Massachusetts General Hospital and another presented at the Biennial Childhood Obesity Conference worked in children, with 84% reducing their BMI after 21 weeks.

“According to recent reports from the World Health Organization, childhood obesity is one of the most serious public health challenges of the 21st century. This is a global public health crisis that needs to be addressed at scale,” said Joanna Strober, co-founder of Kurbo, in a statement about the launch. “As a mom whose son struggled with his weight at a young age, I can personally attest to the importance and significance of having a solution like Kurbo by WW, which is inherently designed to be simple, fun and effective,” she said.

KURBO.

I thought that I hated Weight Watchers. I have not hated them as much as I do right now.

Making weight loss trendy for children is making the development of eating disorders easier and trendier. I am not here for this.

— Anna Sweeney MS, CEDRD-S (@DietitianAnna) August 13, 2019

That said, it’s one thing for a parent to work in conjunction with a doctor to help a child with a health issue, but parents who foist a food tracking app on their kids may not get the same results. In fact, they may even cause the child to develop eating disorders that weren’t present before. (And no, just because a child is overweight, that doesn’t necessarily mean they’re suffering from an “eating disorder.”)

Weight Watchers has a new dieting app for kids as young as 8 and it is truly disturbing https://t.co/GjPl4PHwSv pic.twitter.com/ZMkZmFr9X6

— Dr. Yasmin (@DoctorYasmin) August 14, 2019

There can be many other factors that could be causing a child’s unexpected weight gain, beyond just their interest in eating high-calorie foods. This includes health ailments, hormone or chemical imbalances, medication side effects, puberty and other growth spurts (which can’t always be determined through BMI changes, which are tracked in-app), genetics, and more.

Parents may also be part of the problem, by simply bringing unhealthy food into the house because it’s more affordable or because they aren’t aware of things like hidden sugars or how to avoid them. Or perhaps they’re putting money into a child’s school lunch account, without realizing the child is able to spend it on vending machine snacks, sodas or off-menu items like pizza and chips.

The child may also suffer from health problems like asthma or allergies that have become an underlying issue, making it more difficult for them to be active.

In other words, a program like this is something that parents should approach with caution. And it’s certainly one where the child’s doctor should be involved at every stage — including in determining whether or not an app is actually needed at all.

Powered by WPeMatico

Mint founder Aaron Patzer launches Vital, an ER management tool that integrates with electronic health records

Aaron Patzer launched Mint to help consumers organize their finances. Now he’s raised $5.2 million from investors to launch Vital to bring that consumer-focused mindset to emergency rooms and hospitals to help them organize patient flow.

Patzer co-founded the company with his brother-in-law Justin Schrager, a doctor of emergency medicine at Emory University Hospital. The serial entrepreneur invested a million dollars and two years of peer-reviewed academic study and technical research and development to create Vital, according to a company statement.

Investors in the seed round include First Round Capital and DFJ, Bragiel Brothers, Meridian Street Capital, Refactor Capital and SV Angel. Alongside angel investors Vivek Garipalli, the chief executive of CloverHealth and Nat Turner and Zach Weinberg, the founders of Flatiron Health, these investors are hoping that Patzer can repeat in the healthcare industry the magic he brought to financial services.

“The HITECH* Act was well-intentioned, but now hospitals rely on outdated, slow, and inefficient software – and nowhere is it more painful than in the emergency room,” said Patzer, in a statement. “Doctors and nurses often put more time into paperwork and data entry than patient care. Vital uses smart, easy tech to reverse that, cutting wait times in half, reducing provider burnout and saving hospitals millions of dollars.”

Vital isn’t so much replacing the current system of electronic health records as providing a software integration layer that makes those systems easier to use, according to the company.

It’s basically a two-sided application with a survey for incoming patients. An admitting nurse begins the record and as a next step a patient receives a text to add details like height, weight, recent surgeries, medications and allergies, just as they would on a paper form. Patients can also submit a photo of themselves and their insurance card to expedite the process.

The information is then fed back into a tracking board that doctors and nurses use to prioritize care. A triage nurse then reviews the data and affirms that it is correct by taking vital signs and assessing patients.

All of that data is fed into an algorithm that analyzes the available information to predict a course of treatment and help staff in the emergency room prioritize who needs care first.

Vital’s selling the service to emergency rooms with a starting sticker price of $10,000 per month.

“Vital successfully built software with a modern, no-training-required interface, while also meeting HIPAA compliance. It’s what people expect from consumer software, but rarely see in healthcare,” says First Round investor Josh Kopelman, who’s taking a seat on the company’s board of directors. “Turning massive amounts of complex and regulated data into clean, easy products is what Mint.com did for money, and we’re proud to back a solution that’ll do the same in life and death situations.”

In some ways, Vital looks like the patient-facing admissions side of a coin that companies like Qventus have raised tens of millions of dollars to solve at the systems level.

Powered by WPeMatico

Medivis has launched its augmented reality platform for surgical planning

After two years of development, Medivis, a New York-based company developing augmented reality data integration and visualization tools for surgeons, is bringing its first product to market.

The company was founded by Osamah Choudhry and Christopher Morley who met as senior residents at NYU Medical Center.

Initially a side-project, the two residents roped in some engineers to help develop their first prototypes and after a stint in NYU’s Summer Launchpad program the two decided to launch the company.

Now, with $2.3 million in financing led by Initialized Capital and partnerships with Dell and Microsoft to supply hardware, the company is launching its first product, called SurgicalAR.

In fact, it was the launch of the HoloLens that really gave Medivis its boost, according to Morley. That technology pointed a way toward what Morley said was one of the dreams for technology in the medical industry.

“The Holy Grail is to be able to holographically render a patient,” he said.

For now, Medivis is able to access patient data and represent it visually in a three-dimensional model for doctors to refer to as they plan surgeries. That model is mapped back to the patient to give surgeons a plan for how best to approach an operation.

“The interface between medical imaging and surgical utility from it is really where we see a lot of innovation being possible,” says Morley.

So far, Medivis has worked with the University of Pennsylvania and New York University to bring their prototypes into a surgical setting.

The company is integrating some machine learning capabilities to be able to identify the most relevant information from patients’ medical records and diagnostics as they begin to plan the surgical process.

“What we’ve been working on over this time is developing this really disruptive 3D pipeline,” says Morley. “What we have seen is that there is a distinct lack of 3D pipelines to allow people to directly interface… very quickly try to automate the entire rendering process.”

For now, Medivis is selling a touchscreen monitor, display and a headset. The device plugs into a hospital network and extracts medical imaging to display from their servers in about 30 seconds, according to Choudhry.

“That’s where we see this immediately being useful in that pre-surgical planning stage,” Choudhry says. “The use in surgical planning and being able to extend this through surgical navigation… Streamline the process that requires a large amount of pieces and components and setups so you only need an AR headset to localize pathology and make decisions off of that.”

Already the company has performed 15 surgeries in consultation with the company’s technology.

“When we first met Osamah and Chris, we immediately understood the magnitude of the problem they were out to solve. Medical imaging as it relates to surgical procedures has largely been neglected, leaving patients open to all sorts of complications and general safety issues,” said Eric Woersching, general partner, Initialized Capital, in a statement. “We took one look at the Medivis platform and knew they were poised to transform the operating room. Not only was their hands-free approach to visualization meeting a real need for greater surgical accuracy, but the team has the passion and expertise in the medical field to bring it all to fruition. We couldn’t be more thrilled to welcome Medivis to the Initialized family.”

Powered by WPeMatico